Home
    Scientific Program
    Registration
    Accommodation
    Contact
     Home
     Welcome Note
     Committees
     Timetable
     Scientific Program
     Faculty
     Poster Presentation Schedule
         Group A
         Group B
         Poster Presentation Guidelines
     Registration
     Accommodation
         Pullman Montparnasse
     Sponsorship & Exhibition
     Sponsors
     CME
     General Information
         Italian Agent
         Before you travel...
         2012 Congress feedback lottery
     Invitation Letter
     Partners
     About Paris
     Past Congresses
     CURy 2010 Webcasting
The 4th World Congress on
Controversies in Urology (CURy)
Paris, France, January 27-30, 2011
  Scientific Program Print
Friday, January 28, 2011
    
Session 1
08:30-10:00
Hall A 
LESS Surgery
(Supported by an unrestricted grant of Olympus Medical Systems GMBH)
   
Chairpersons:
A. Alcaraz, Spain; E. Barret, France
  
08:30-08:45
 
  
08:45-09:00
 
  
09:00-09:15
   
  
09:15-09:30
  
  
09:30-09:45
  
   
09:45-10:00
LESS: What is new?
J.-U. Stolzenburg, Germany
   
LESS in Urological Surgery
A. Figueiredo, Portugal
  
LESS: Transvaginal nephrectomy
A. Alcaraz, Spain
 
LESS: Radical Prostatectomy
F. Gaboardi, Italy
 
LESS and Robotics
E. Barret, France
 
Q&A
     
   
  
Session 2
08:30-10:00
Hall B
Diagnosis & Imaging of Prostate Cancer
 
   
Chairpersons:
N. Fleshner, Canada; P. Mozer, France 
    
08:30-08:45
    
 
08:45-09:00
    
  
09:00-09:15
 
  
09:15-09:30
    
 
09:30-09:45
 
  
09:45-10:00
Prostate Biopsy: Update
N. Fleshner, Canada   
 
PCA3 and other tissue biomarkers: Current status
A. De La Taille, France
    
PSA, SNP and other New Markers
A. Zlotta, Canada
  
MRI in early PCA
A. Villers, France
  
Histoscanning
J. Braeckman, Belguim
   
Q&A 
    
 
10:00-10:30
Coffee Break & Poster Viewing
    
    
Session 3
10:30-12:00
Hall A
Treating Bone Disease across the Prostate Cancer Continuum of Care
(Supported by an unrestricted grant of Amgen)
  
Chairpersons:
N. Clarke, UK; M. Colombel, France
  
 
The silent risk of cancer treatment induced bone loss (CTIBL): How should we manage our patients on ADT?
J. Brown, UK
       
RANK Ligand inhibition: Challenging the standard of care for bone health in men with advanced prostate cancer
K. Fizazi, France
  
Extending bone-metastases free survival in men with prostate cancer: Future prospects with RANK Ligand inhibition
S. OudardFrance
    
    
        
      
Session 4
10:30-12:00
Hall B
Non-Muscle Invasive Bladder Cancer (NMIBC): White light cystoscopy, blue light cystoscopy, narrow band imaging, virtual cystoscopy? 
What should the urologist use in 2011?
A Case Discussion Panel
(Supported by an unrestricted grant of GE Healthcare)
Chairpersons:
J.A. Witjes, The Netherlands; A. Zlotta, Canada
  
10:30-10:45
   
 
10:45-11:05
   
  
11:05-11:25
   
     
11:25-11:45
    
     
11:45-12:00
The value of cytology, pathological limitations of staging and grading of NMIBC and CIS
E. Comperat, France
 
Narrow-band imaging (NBI)
T. De Reijke, The Netherlands
      
Virtual cystoscopy and 3D reconstruction of the Upper Urinary Tract (UUT)
A. Stenzl, Germany    
      
A new in-bladder device for follow-up: Wireless Capsule Endoscopy
A. Neheman, Israel  
     
Hexaminolevulinate guided fluorescence cystoscopy (PPD) and thermo-chemotherapy
J.A. Witjies, The Netherlands  
  
  
 
  
Session 5
12:00-13:30
Hall A
Multidisciplinary Care in Prostate Cancer: Decrease the Barriers and Grasp the Benefits
(Satellite Symposium sponsored by Astellas Pharma Europe Ltd.)
  
Chairperson:
J. Irani, France
  
 
Introduction
Chair
 
Multidisciplinary care in prostate cancer: View of the surgeon
P. Bastian, Germany
    
Multidisciplinary care in prostate cancer: View of the radiation oncologist
M. van Vulpen, The Netherlands
  
Multidisciplinary care in prostate cancer: View of the brachytherapist
J.-M. Cosset, France
    
Multidisciplinary care in prostate cancer: Benefits for the patient
B. Tombal, Belgium
   
Discussion and take home messages
Chair, faculty & participants
 
  
    
13:30-14:30
Bistro Break
        
  
Session 6
14:30-16:00
Hall A 
The Challenge of Managing Male LUTS: Do the Guidelines Provide Real Guidance?
(Supported by an unrestricted grant of Astellas Pharma Europe Ltd.)
  
Chairpersons:
F. Desgrandchamps, France & J. Fitzpatrick, Ireland
   
14:30-15:00
    
  
15:00-15:30
    
  
15:30-16:00
Controversy 1: Diagnosis of male LUTS: Piece of cake!
M. Oelke, Germany
    
Controversy 2: Individualizing treatment for male LUTS is the future!
E. Chartier-Kastler, France
    
Controversy 3: Why bother treating storage symptoms in men?
C. Llorente, Spain 
      
   
  
Session 7
14:30-16:00
Hall B
Low Risk Prostate Cancer: The case of active surveillance and focal therapy
(Partially supported by an unrestricted grant form Steba Biotech)
   
Chairpersons 
L. Klotz, Canada; A. Villers, France
    
14:30-14:45
    
  
14:45-16:00
 
  
  
14:45-14:52
 
 
14:52-15:00
 
   
15:00-15:08
 
 
15:08-15:16
 
  
15:16-15:24
  
  
    
15:24-15:32
  
  
     
15:32-15:40
  
      
15:40-16:00 
Active surveillance
L. Klotz, Canada
        
Which focal therapy?  Panel discussion
Moderator: 
A. Villers, France
      
Pathological basis for focal therapy
A. Villers, France
  
HIFU in low risk prostate cancer
C. Robertson, USA
   
In bore MR guided robot assisted focal laser therapy of prostate cancer
J. Trachtenberg, Canada 
     
Cryo-ablation in low risk prostate cancer
U. Witzsch, Germany
    
Vascular targeted photodynamic therapy with TOOKAD® Soluble in patients with low risk prostate cancer
M. Emberton, UK
  
Correlation between histological results and MR imaging after vascular targeted photodynamic therapy with TOOKAD® Soluble in focal therapy
A.R. Azzouzi, France
      
The case against active surveillance and focal treatment
M. Graefen, Germany
  
Discussion
  
  
 
16:00-16:30
Coffee Break & Poster Viewing
      
   
Session 8
16:30-18:00
Hall A
A Multidisciplinary Treatment Team Approach to Metastatic Hormone-Refractory Prostate Cancer
(Satellite Symposium sponsored by Sanofi-Aventis)
  
Chairpersons:
F. Saad, Canada; S. Oudard, France
  
16:30-16:35
 
 
16:35-17:00
 
 
 
17:00-17:25
  
  
  
17:25-17:50
 
 
 17:50-18:00
Welcome and Introduction
F. Saad, Canada
  
Treatment of high-risk patients with advanced prostate cancer using a multi-disciplinary approach
B. Tombal, Belgium
C. Sternberg, Italy
      
Management of mHRPC patients previously treated with docetaxel -
Critical analysis of the data
S. Oudard, France   
    
Management of mHRPC patients previously treated with docetaxel -Practical Application of the data
M. Eisenberger, USA
  
Group discussion and meeting close
F. Saad, Canada       
S. Oudard, France
All
 
     
    
  
Session 9
16:30-18:00
Hall B
Localized Kidney Cancer
 
 
Chairpersons:
G. Morgia, Italy; M. Soloway, USA
    
16:30-16:45
   
 
16:45-18:00
Are there still contraindications to partial nephrectomy?
J. Patard, France
   
Case Discussion Panel: 3cm tumor in a 70-year old patient
Case presenter:
G. Morgia, Italy
 
Discussants:
The place for
...Surveillance
J. Patard, France
 
...Ablative minimally invasive treatment
B. Malavaud, France
 
...Open Surgery
Z. Dotan, Israel
  
...Laparoscopy
A. Finelli, Canada
 
...Robotic
C. Vaessen, France
 
 
  
  
  
Saturday, January 29, 2011
  
Session 10
08:30-10:00
Hall A
Hot News from 2010 Congresses
  
  
Moderator:
L. Boccon-Gibod, France; R. Burette, Belgium; K. Fizazi, France
  
08:30-09:00
   
  
09:00-09:30
   
  
09:30-10:00
 
Prostate cancer
J. van Moorselaar, The Netherlands
  
Bladder cancer 
J. Irani, France
  
Renal cancer
A. Alcaraz, Spain 
     
        
  
  
Session 11
08:30-10:00
Hall B
Surgical Treatment of Female Stress Urinary Incontinence
 
 
Chairpersons:
F. Cruz, Portugal; V. Delmas, France
    
08:30-08:45
  
 
      
08:45-09:00
  
  
09:00-09:15
  
  
   
09:15-09:30
  
  
09:30-09:45
  
  
09:45-10:00 
 
Retropubic and transobturator tension-free suburethral slings: What have we achieved in the past 15 years?
E. Costantini, Italy
      
Small is beautiful?  Can single incision suburethral slings compare to tension-free slings?
F. Cruz, Portugal 
 
Which risk factors can affect the success of suburethral slings?  What should we tell our patients:
J. Heesakkers, The Netherlands
 
Dysfunctional voiding after a suburethral sling: How can it be prevented, detected and treated:
V. Delmas, France
 
Do bulking agents/balloons have a place in the treatment of female SUI?
D. Yachia, Israel
 
Do MUS have an effect on female sexual function?
E. Costantini, Italy
 
Discussion & Conclusions
 
     
   
10:00-10:30
Coffee Break & Poster Viewing
   
   
Session 12
10:30-12:00
Hall A
GnRH-receptor blockers: A new era for GnRH analogues?
(Supported by an unrestricted educational grant from Ferring Pharmaceuticals)
       
Chairpersons C. Schulman, Belguim; L. Boccon-Gibod, France
   
10:30-10:35
Welcome and Objectives
L. Boccon-Gibod, France
   
10:35-10:55
Development of a new GnRH blocker
B.-E. Persson, Switzerland
   
10:55-11:15
Locally advanced prostate cancer: The role of surgery in combination treatments.
F. Montorsi, Italy
   
11:15-11:35
Androgen deprivation with radiation: When? For how long?
M. Mason, UK
   
11:35-11:55
What patients benefit from a GnRH blocker?
T. Keane, USA
   
11:55-12:00
Conclusions
C. Schulman, Belgium
  
  
 
  
Session 13
10:30-12:00
Hall B
Muscle Invasive Bladder Cancer: Is There a Place for Conservative Management?
 
    
Capsule:
Role of a strong multidisciplinary collaboration
Chairperson:
M. Soloway, USA & A. Stenzl, Germany
  
10:30-12:00
 
 
A debate and case panel discussion: A multidisciplinary team approach 
 
PRO
R. Burette, Belgium
N. Clarke, UK
A. Zlotta, Canada
 
CON
Y. Fradet, Canada
U. Studer, Switzerland
M. Zerbib, France
    
   
 
Session 14
12:00-13:30
Hall A
Urologists, RCC and targeted agents: Applying Clinical Evidence to Clinical Practice
(Satellite Symposium sponsored by Pfizer Oncology)
  
 
Welcome and introduction
C. Sternberg, Italy
   
Selecting Targeted Agents for the Treatment of Advanced RCC
C. Sternberg, Italy
  
Getting the Best from Targeted Agents in Clinical Practice: The Importance of Therapy Management
M. Kuczyk, Germany
    
Current and Future Role in Surgery in the Era of Targeted Agents
A. Bex, The Netherlands
 
Discussions and Q&A
Panel
   
Summary and close
C. Sternberg, Italy  
 
    

13:30-14:30
Bistro Break
           
    
Session 15
14:30-16:00
Hall A
Is the Gold Standard turning Green? Breakthrough Innovation in GreenLight
(Satellite Symposium sponsored by American Medical Systems)
  
Chairperson:
A. Bachmann, Switzerland
  
 
Why do we need more and more laser to treat BPH?
O. Reich, Germany
   
GreenLight HPS laser for the treatment of BPH: functional results with long-term follow-up
G. Alivizatos, Greece
  
The speed of light just went faster
F. Gomez Sancha, Spain
    
Is GreenLight XPS as fast and safe as TURP?
A. Bachmann, Switzerland
 
Prostate surgery - the transition from PV to XPS 
J.A. Thomas, UK
 
Is GreenLight XPS now better for the patients or the surgeons?
O. Reich, Germany
   
        
  
 
Session 16
14:30-16:00
Hall B
Kidney Stone & Endourology
 
    
Chairpersons:
D. Tolley, UK; O. Traxer, France
  
14:30-15:00
  
  
  
  
15:00-15:30
 
 
 
 
15:30-16:00
  
Indications for Mini-Perc vs. Flexible URS: A debate
(Debate sponsored by Karl Storz)
Mini Perc: T. Knoll, Germany
Flexible URS: O. Traxer, France
  
Management of ureteral impacted stone: ESWL vs. URS vs. Lap surgery
ESWL: D. Tolley, UK
URS: O. Traxer, France
Lap surgery: H. Winkler, Israel
    
ESWL: Can we improve outcomes?
With novel technologies?
Clinically: Patient selection, patient stone factors
D. Tolley, UK 
O. Traxer, France
H. Winkler, Israel
  
 
16:00-16:30
Coffee Break & Poster Viewing
       
 
Session 17
16:30-17:30
Hall A
New Drugs and Technology Coming Soon to Your Practice
 
    
Chairpersons:
P. Rischmann, France; R. Vela Navarrete, Spain
  
16:30-16:40
   
   
16:40-16:50
   
    
16:50-17:00
   
   
17:00-17:10
      
    
17:10-17:20
     
    
  
17:20-17:30
 
 
Uro-oncology: From our Bench to your Bedside 
E. Baskin-Bey, UK
  
Provenge
K. Fizazi, France
  
Abiraterone in castration resistant prostate cancer
G. Attard, UK 
 
A unique profile makes Silodosin different
F. Montorsi, Italy   
 
Sacral neuro-stimulation in idiopathic detrusor overactivity (IDO) and neurogenic detrusor overactivity (NDO)
E. Chartier-Kastler, France 
     
Botox in idiopathic detrusor overactivity (IDO) and neurogenic detrusor overactivity (NDO)
F. Cruz, Portugal
      
         
  
 
Session 18
16:30-17:30
Hall B
BPH Surgery: Gold Standard Surgery vs. Novel Technologies
 
    
Chairpersons:
G. Alivizatos, Greece; M. Zerbib, France
  
16:30-17:30
 
16:30-16:40
 
16:40-16:50
 
16:50-17:00
 
17:00-17:10
 
17:10-17:20
   
17:20-17:30
    
Surgery for prostate 80 gram or more
   
Open simple prostatectomy: M. Zerbib, France

TURP: A. Skolarikos, Greece

TUR in saline: P. Geavlete, Romania

Green light laser: P. Whelan, Canada      
        
 
Laser enucleation/HoLEP: R. Saglam, Turkey
  
Discussion
         
   
  
 
Sunday, January 30, 2011
    
Session 19
09:00-09:30
 
   
09:30-11:00
Hall A
 
State of the Art: Patient safety and quality control is mandatory in urology
N. Fleshner, Canada
  
Nerve-Sparing Radical Prostatectomy: How I do it
Open vs. Laparoscopic vs. Robotic
 
Chairpersons:
P. Coloby, France; F. Montorsi, Italy
 
09:30-11:00  
   
HOW I DO IT: Videoclips
  
Pelvic lymphadenectomy
A. De La Taille, France
S. Egawa, Japan
H. Huland, Germany
F. Montorsi, Italy
  
Control of Santorini's plexus 
C. Abbou, France
J. Moul, USA
T. Piechaud, France
 
Nerve-sparing extirpation of the prostate
C. Barre, France
A. De La Taille, France
S. Egawa, Japan
H. Huland, Germany
T. Piechaud, France
  
Dissection of seminal vesicles
C. Abbou, France
F. Montorsi, Italy
J. Moul, USA
 
Bladder neck dissection
C. Barre, France
S. Egawa, Japan
T. Piechaud, France
 
Panel discussion
Nerve-sparing: Why open should not be considered dead
H. Huland, Germany & J. Moul, USA
  
Nerve-sparing: Why laparoscopic should not be considered dead
C. Abbou, France & S. Egawa, Japan
  
Nerve-sparing: Why robotics will kill everything else
T. Piechaud, France & A. De La Taille, France
 
       
   
11:00-11:30
Coffee Break
       
   
Session 20
11:30-13:00
Hall A
Radical Cystectomy: How I do it
Open vs. Laparoscopic vs. Robotic
   
Chairpersons:
R. Hautmann, Germany; M. Soloway, USA; U. Studer, Switzerland
 
11:30-13:00
Open Sugery
R. Hautmann, Germany
A. Stenzl, Germany
U. Studer, Switzerland
 
Laparoscopic surgery
C. Abbou, France
F. Rozet, France
 
Robotic surgery
A. Mottrie, Belgium
C. Vaessen, France
 
Summary discussion
      
   
 
13:00-13:30
Drinks and Sandwiches
       

Home   
Copyright © 2007 comtecmed.com. All rights reserved.   The website was last updated on 05/11/2011 Created by     WebStudio.co.il